Seattle biotech entrepreneur floating $15M IPO

Veteran Seattle biotech player Steven Quay wants to fund his diagnostic testing company, Atossa Genetics, through a $15 million IPO. No underwriters are signed on yet, though. Quay is the former CEO of Sonus and Nastech, explains Xconomy, neither of which have fared well. Report

Suggested Articles

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.

VBL got the green light after the committee looked at unblinded overall survival data for the second pre-planned interim analysis.

Eleusis researchers discovered that structural characteristics of the 2C-H class of psychedelics help to control asthma without behavioral effects.